What changed in this filing

/stocks — the workspaceLOADING

Item 2. Properties

2023-03-13 compared with 2022-03-14 · 24 added, 33 removed, 5 unchanged (92% of the section changed)

2 – PROPERTIES

We maintain our principal office at 26 Main Street, Suite 101, Chatham,

New Jersey 07928.

Our telephone number at that office is (862) 799-8599 and our fax number is (212) 923-5700.

On August 28, 2020, we entered

into a lease, whereby we agreed to lease new office space, commencing September 2020 and expiring December 2025.

In connection therewith,

we maintain a letter of credit, which has a remaining balance of $139,729 as of December 31, 2021, and such amount is deposited into the

restricted cash account maintained at the bank that issued the letter of credit.

The total square footage of our principal office space

is approximately 4,269.

December 6, 2018, we entered into a lease amendment, whereby we agreed to lease new office space in New York, New York, commencing

January 15, 2019, and expiring on November 30, 2020.

maintain our principal office at 26 Main Street, Suite 101, Chatham, New Jersey 07928.

Our telephone number at that office is (862) 799-8599

and our fax number is (212) 923-5700.

On August 28, 2020, we entered into a lease, whereby we agreed to lease new office space, commencing

September 2020 and expiring December 2025.

In connection therewith, we maintain a letter of credit, which has a remaining balance of $140,201

as of December 31, 2022, and such amount is deposited into the restricted cash account maintained at the bank that issued the letter of

December 6, 2018, we entered into a lease amendment, whereby we agreed to lease new office space in New York, New York, commencing January

15, 2019, and expiring on November 30, 2020.

In August 2020, we signed a one-year extension, expiring in November 2021.

In September 2021, we signed a one-year extension, expiring in November 2022.

In connection therewith, we maintain a letter of

credit, which has a remaining balance of $100,314 as of December 31, 2021, and such amount is deposited into the restricted cash

account maintained at the bank that issued the letter of credit.

The total square footage of our office space is approximately

On October 1, 2021, we completed the purchase of a research and development

facility in Maryland totaling $17.5 million, to process development activities.

As of December 31, 2021, the asset was operational but

the asset was not ready for its intended use.

It is our intention to have the facility ready for use in the first half of 2022.

March 5, 2021, we announced that we had entered into a $2.9 million non-binding Purchase and Sales Agreement in connection with

a property in Massachusetts that is expected to close in the second quarter of 2022.

The Property is intended for process development

On December 23, 2020, we completed

the purchase of our approximately 44-acre site in Hamilton, Montana for $4.5 million, for the construction of a vaccine development and

commercial scale manufacturing facility.

As of December 31, 2021, the facility was not ready for its intended use.

On September 28, 2020, we completed

the purchase of our 40,000 square foot facility in Massachusetts for $4.0 million, to house our new Advanced Development Center for accelerated

development and manufacturing of vaccines.

As of December 31, 2021, the facility was not ready for its intended use.

In September 2021,

we signed a one-year extension, expiring in November 2022.

In May 2022, we signed a one-year extension, expiring in November 2023.

connection therewith, we maintain a letter of credit, which has a remaining balance of $100,653 as of December 31, 2022, and such amount

is deposited into the restricted cash account maintained at the bank that issued the letter of credit.

October 1, 2021, we completed the purchase of a research and development facility in Maryland totaling $17.5 million, to process development

As of December 31, 2022, the asset was operational and the asset was ready for its intended use.

December 23, 2020, we completed the purchase of our approximately 44-acre site in Hamilton, Montana for $4.5 million, for the construction

of a vaccine development and commercial scale manufacturing facility.

As of December 31, 2022, the facility was not ready for its intended

September 28, 2020, we completed the purchase of our 45,000 square foot facility in Massachusetts for $4.0 million, to house our new Advanced

Development Center for accelerated development and manufacturing of vaccines.

As of December 31, 2022, the facility was operational and

ready for its intended use.

minimum lease payments are as follows (in thousands):

Year Ending December 31,

Included interest

believe that our existing facilities are suitable and adequate to meet our current business requirements.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 2. Properties